ABSTRACT In previous studies we have shown that oxolinic acid, a specific inhibitor of the A subunit of DNA gyrase, induces DNA cleavage at 100,000-base-pair intervals on the Escherichia coli chromosome. At subsaturating drug concentrations, cleavage is induced at a fraction of these sites and DNA synthesis is partially inhibited. This partial inhibition is surprisingly rapid even when few sites have been inactivated. We now report kinetic measurements suggesting that inactivation of 100,000 base-pair gyrase sites by oxolinic acid does not inhibit DNA synthesis by simply producing barriers to replication fork movement. Slowing the rate of fork movement, thus increasing the time for a fork to reach a barrier, fails to proportionately slow inhibition of DNA synthesis. Moreover, the initial, rapid phase of inhibition is followed by a slower decline that is not accelerated by increasing the frequency of barriers by raising drug concentrations. These data, when added to the observation that additional oxolinic acid-induced cleavage occurs in replicating regions of the chromosome, suggest that gyrase may function at replication forks as well as at 100,000-base-pair intervals on the chromosome.
From the time Cairns (1) first demonstrated that the Escherichia coli chromosome is a circular DNA molecule, it has been clear that a topological problem arises when DNA strands separate during replication. As the strands at the replication fork separate, twisting stress tends to tighten the double helix ahead of the fork, causing the DNA to become positively supertwisted. The cell must be able to relax these supertwists to allow replication to proceed. The enzyme DNA gyrase (ref. 2 ; DNA topoisomerase II) can provide the solution to this topological problem in E. coli by introducing negative supertwists into DNA (for a review, see ref. 3) . Gyrase is composed of two types of subunits, a nicking-closing activity coded by gyrA, which is inhibited by nalidixic and oxolinic acids (4, 5) , and an ATPase coded by gyrB, which is sensitive to coumermycin A1 and novobiocin (6) . These drugs inhibit DNA synthesis in bacteria, providing evidence that gyrase functions in DNA replication. Additional support for this conclusion comes from the demonstration that DNA replication stops at nonpermissive temperatures in gyrA temperature-sensitive (ts) mutants (7) . In vitro studies of gyrase have led to the discovery of a related enzymatic activity (refs. 8 and 9; topoisomerase II') which can also satisfy the topological requirements for DNA replication. It relaxes both positive and negative supertwists. The function of these two topoisomerases in chromosome biology is largely unknown.
Studies using inhibitors lead to several conclusions about relationships between gyrase and the bacterial chromosome. Coumermycin A1 prevents superinfecting bacteriophage X DNA from becoming supertwisted (6, 10) and also relaxes the supertwists in the E. coli chromosome (11) . Thus, it is likely that gyrase both establishes and maintains superhelical tension in the bacterial chromosome. Oxolinic acid, on the other hand, induces a sodium dodecyl sulfate (NaDodSO4)-dependent cleavage of E. coli DNA. Cleavage produces large [100-kilobase-pair (kbp)] DNA fragments, indicating that at least the A subunit of gyrase is located at roughly 50 sites on the chromosome (12) . Both antibiotics inhibit chromosomal DNA synthesis, but the mechanisms of action differ. Inhibition by coumermycin A1 is relatively slow and correlates with loss of DNA superhelical density (11) . In contrast, inhibition by oxolinic acid is rapid, and little or no change is observed in DNA superhelicity (12) . Oxolinic acid is thought to block the nicking-closing reaction of gyrase by trapping a reaction intermediate in which gyrase is stably attached to both strands of the DNA (13) . Thus, this drug may inhibit DNA synthesis by combining with gyrase to form a barrier to replication fork movement. At subsaturating oxolinic acid concentrations, a fraction of the 100-kbp gyrase sites are inactivated and DNA synthesis is partially inhibited (12) . Partial inhibition, however, is surprisingly rapid even at low drug concentrations (12) .
We suggested (12) The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. uvrA6) were obtained from A. J. Clark (University of California, Berkeley); and N99 and N4177, a gyrB (cour ts) transductant of N99, were obtained from M. Gellert (National Institutes of Health).
All strains were grown in M9 minimal salts medium (16) supplemented with amino acids (20 tig/ml) or thymine (40 ,tg/ml) (or both) as necessary.
Measurement of DNA Synthesis. The rate of DNA synthesis was determined by transferring 0.2 ml from exponentially growing bacterial cultures to tubes containing 1 gCi of [3H]-thymidine. These samples were then incubated at 370C for 2 min; incorporation of radioactivity was terminated by addition of 2 ml of cold 5% (wt/vol) trichloroacetic acid. Acid precipitates were collected on Whatman GF/A filters, washed with cold 5% trichloroacetic acid, then with 95% ethanol, and then dried. Acid-precipitable radioactivity measured by liquid scintillation counting was taken as a measure of the rate of DNA synthesis.
Velocity Sedimentation Analyses. Exponentially growing, radioactively labeled E. coli were concentrated and lysed as described (12) . Lysates were warmed to 200C and layered on 5-20% linear sucrose density gradients containing 0.1 M NaCl, 50 mM sodium phosphate buffer (pH 6.8), and 0.5% NaDod-SO4. Centrifugation was performed in a Beckman SW 50.1 rotor at 230C for times and speeds indicated in the figure legends. Fractions were collected, DNA was precipitated, and radioactivity was determined as described (12) . RESULTS Kinetics of Inhibition of DNA Synthesis by Oxolinic Acid. Addition of oxolinic acid to exponentially growing cultures of E. coli causes the rate of DNA synthesis to decline rapidly. The extent of inhibition depends on the drug concentration and is proportional to the number of gyrase sites inactivated (12) . As expected, no inhibition occurs in gyrA (oxor) mutants (data not shown), confirming gyrase as the target of oxolinic acid.
We can propose two simple models to account for oxolinic acid inhibition of DNA synthesis. The first model assumes that forks are randomly distributed relative to inactivated 100-kbp gyrase sites in exponentially growing cells and that inhibition arises whenever a replication fork encounters an inactivated, 100-kbp gyrase site or enters a domain governed by that site. This model predicts monophasic inhibition kinetics. The second model postulates that additional gyrase molecules are located close to forks in replicating regions of the chromosome. Inactivation of these sites blocks replication immediately and produces a rapid decline in synthesis. Forks surviving the initial, rapid inactivation would continue to replicate until reaching the terminus of replication. These surviving forks should decay at a slower rate than those initially blocked by the drug. Thus, this model predicts biphasic inhibition kinetics.
In order to determine whether decay of synthesis has one or two kinetic phases, it is necessary to eliminate contributions made by repair mechanisms to DNA synthesis rates. Cellular repair mechanisms quickly respond to oxolinic acid damage:
DNA synthesis rates increase shortly after the initial inhibitory phase (see Fig. 1A ), obscuring measurement of DNA synthesis due to surviving forks. However, many of these secondary effects depend on induction of the recA gene and are eliminated in recA and lexA mutants (17) . Fig. 1B shows a substantial reduction in residual DNA synthesis when a recA -strain was treated with oxolinic acid. Measurements over a wide range of subsaturating drug concentrations (below 1 Ag/ml) with recA and lexA mutants showed results similar to those illustrated in Fig. 1B . The uvr pathway, the other major repair pathway in E. coli, appears not to be involved in repair of oxolinic acid- (recA-). 0, Untreated control; ,, oxolinic acid, 0.25 ,g/ml; 0, oxolinic acid, 1.5,ug/ml. induced damage. Inhibition of synthesis in uvrA and uvrA recA mutants was identical to that found in wild-type and recAstrains, respectively (data not shown).
Initiation of new rounds of replication could also contribute to residual DNA synthesis rates. This can be eliminated by pretreating the cells with either chloramphenicol (Fig. 2A) or rifampicin (Fig. 2B) , inhibitors of protein and RNA synthesis, respectively, which allow forks to continue to elongate but not to reinitiate (for a review, see ref. 18 ). When reinitiation and recA-dependent repair processes were both blocked, the decay of DNA synthesis had biphasic kinetics (Fig. 2, triangles) . This finding is consistent with the second model described above, in which some gyrase molecules function close to replication forks.
Although the extent of the rapid phase of inhibition increased as oxolinic acid concentrations were raised, the slopes of the slow phase did not become markedly steeper (see Fig. 2 Fig. 3 show that inhibition was rapid at both temperatures and was largely complete by 2-3 min after drug addition. This is faster than expected if inhibition were to occur only at the distributed targets; lowering the temperature to 190C reduces the rate of synthesis by a factor of 5, thus requiring about 10 min for a fork to traverse the 100-kbp interval between targets [at 370C, a round of replication takes about 40 min (18, 19) so each of the two forks polymerizes 50 kbp per min].
The data in Fig. 3 control; *, oxolinic acid alone, 0.1 ,gg/ml; 0, chloramphenicol alone, 40 yg/ml; A, chloramphenicol followed by oxolinic acid, 0.1 ,ug/ml; A, chloramphenicol followed by oxolinic acid, 0.2 ,g/ml. (B) Effect of rifampicin (Rif) added 5 min prior to oxolinic acid. 0, Untreated control; *, oxolinic acid alone, 0.1 ,ug/ml; 0, rifampicin alone, 50 gg/ml; A, rifampicin followed by oxolinic acid, 0.1 Asg/ml; A, rifampicin followed by oxolinic acid, 0.25 gg/ml. Untreated controls at the time of addition of chloramphenicol or rifampicin were 11,500 cpm or 7300 cpm, respectively. temperature also reduces inhibition. We have not explored this phenomenon further.
Oxolinic Acid Induces Additional DNA Cleavage in Pulse-Labeled DNA. The kinetic measurements described above suggest that inactivated 100-kbp gyrase sites may not cause inhibition of DNA synthesis. If inhibition arises from additional sites of oxolinic acid-gyrase interaction located near replication forks, these additional sites might be susceptible to oxolinic acid/NaDodSO4-induced cleavage. If so, DNA close to replication forks would be smaller than bulk DNA when obtained from NaDodSO4-containing lysates of oxolinic acidtreated cells. This possibility was examined by comparing the sedimentation rate of pulse-labeled DNA (3H-labeled) with that of long-term-labeled DNA ("4C-labeled) from such a lysate.
Data obtained from strain DG 75 grown at 19°C show (Fig. 4) that pulse-labeled DNA sediments at about half the rate of long-term-labeled DNA in neutral sucrose density gradients. By using the Burgi-Hershey (20) gyrase sites adjacent to forks. Thus, the fraction of 3H found in 15-kbp fragments was much smaller than seen in Fig. 4 . The following control experiments indicate that DNA fragmentation arises from oxolinic acid-gyrase interactions. More than 80% of the pulse-labeled DNA was 200 kbp or larger when oxolinic acid was omitted or when lysates from drugtreated cells were incubated at 600C for 10 min prior to addition of NaDodSO4 (data not shown). Because this thermal treatment blocks cleavage at gyrase sites (12), we would have observed production of 15-kbp fragments from other sources such as nucleases, cellular repair mechanisms, or shear-sensitive regions. These fragments did not arise from cleavage due to radioactive decay from high specific activity 3H; both isotopes sediment as 100-kbp fragments when the pulse label is followed by a chase for 1/8th generation (data not shown).
Blockage of Oxolinic Acid-Induced Inhibition of DNA Synthesis by gyrB (ts) Mutation. The data described above concern only the product of gyrA; they provide no information concerning the B subunit of gyrase. If both A and B subunits function together near replication forks, thermal treatments of bacteria containing a temperature-sensitive mutation in gyrB might alter the inhibition of DNA synthesis induced by oxolinic acid. This appears to be the case. When a gyrB (ts) mutant was shifted to 420C prior to addition of oxolinic acid, the subsequent effect of the drug was reduced (compare triangles in Fig. 5A ); DNA synthesis rates became higher even though the thermal treatment alone inhibited DNA synthesis (Fig. SA) . A smaller, but significant reduction in drug sensitivity was also seen in the wild-type strain (Fig. 5B) . The two strains could be compared after the rates of DNA synthesis in the presence of oxolinic acid were normalized to those in the absence of the drug. Fig. 5C shows that at 42°C oxolinic acid concentrations that inhibited DNA synthesis by 90% in the wild-type strain caused only a 50% reduction in the mutant. In the reciprocal experiment, in which oxolinic acid was added prior to the temperature shift, inhibition of DNA synthesis by oxolinic acid was partially reversed by the shift to higher temperature. The gyrB (ts) mutant and the wild-type strains are compared in Fig. 5D , in which the rates of DNA synthesis after the temperature shift have again been normalized to rates of controls not treated with oxolinic acid. In the mutant strain, 50% of the DNA synthesis rate was recovered after the temperature shift compared to 10% recovery in the wild type. Thus, in vvo both subunits of gyrase appear to be involved in DNA synthetic processes blocked by oxolinic acid.
DISCUSSION
Oxolinic acid has the unusual property of inhibiting bacterial DNA synthesis rapidly even at subsaturating concentrations (12) . The target of the drug, DNA gyrase (4, 5) , is distributed at 100-kbp intervals on the chromosome (12) , and the extent of inhibition of synthesis is proportional to the number of gyrase sites interacting with the drug (12) . Drug-gyrase complexes could act as barriers to replication fork movement, but if they occur only at 100-kbp intervals, the expected kinetics of inhibition would be monophasic rather than biphasic (see Fig. 2 ). Moreover, increasing the drug concentration, and thereby increasing the number of blocked 100-kbp gyrase sites, has little effect on the fractional decay rate of synthesis in the slow phase of inhibition (Fig. 2) . Consequently, it is unlikely that inhibition arises from replication forks' stopping at blocked 100-kbp gyrase sites. This argument is supported by the observation (Fig.  3 ) that reducing the rate of fork movement by 80% fails to slow inhibition significantly, even though the length of time to reach barriers distributed at 100-kbp intervals should have increased proportionately.
Although inactivated 100-kbp gyrase sites do not act as simple barriers to fork movement, bacterial chromosomes might be organized in such a way that inactivation of one or a few of these sites could stop DNA movement by locking the chromo- In the standard assay, this value was 13,000 cpm. (C) Rates of synthesis in the presence of oxolinic acid normalized to rates in the absence of the drug for the gyrB (ts) mutant (0) and wild-type (0) strains after a shift to 420C as shown in A and B. Zero time is at the point of drug addition.
(D) Reciprocal experiment in which oxolinic acid (1.5 ,g/ml) was added to cultures 9 min prior to the shift from 30°C to 42°C. As in C, rates of synthesis in the presence of the drug are normalized to those in the absence of the drug. Zero time is at the time of temperature shift. 0, gyrB (ts); 0, wild type. would make less likely the possibility that oxolinic acid and gyrase interact to form a poison unrelated to normal gyrase function (7) .
Although no molecular differences have been found that distinguish the two levels of gyrase action, the observations described above emphasize the importance of understanding where and how gyrase is distributed on the chromosome. Gyrase clearly shows a preference for cleavage sites in vitro (4, 5, 22, 
